Stem Cell Therapy finalizes merger with South Korean firm

02/1/2010 | American City Business Journals

Stem Cell Therapy International has completed its merger with South Korean firm Histostem in a deal that will allow it to run Histostem as its wholly owned unit. Stem Cell Therapy, a provider of biological supplies containing new stem cell product lines, plans to operate under the name AmStem.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX